Ozoralizumab: First Approval

被引：51

作者：

Keam, Susan J. ^{[1
]}

机构：

[1] Springer Nat, Private Bag 65901, Auckland 0754, New Zealand

来源：

DRUGS | 2023年 / 83卷 / 01期

关键词：

RHEUMATOID-ARTHRITIS;

D O I：

10.1007/s40265-022-01821-0

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Ozoralizumab (Nanozora (R)), a trivalent anti-tumour necrosis factor alpha (TNF alpha) NANOBODY (R) compound, has been developed by Taisho Pharmaceutical Co. Ltd (under license from Ablynx, an affiliate of Sanofi) for the treatment of rheumatoid arthritis (RA). In September 2022, ozoralizumab was approved in Japan for the treatment of RA that is inadequately managed by current available treatments. This article summarizes the milestones in the development of ozoralizumab leading to this first approval.

引用

页码：87 / 92

页数：6

共 18 条

[1]

Ablynx, 2018, ABL SIGNS EXCL LIC A

[2]

Fleischmann R, 2011, ACRARHP ANN SCI M

[3]

Fleischmann RM, 2012, ARTHRITIS RHEUM-US, V64, pS563

[4] 2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis [J].

Fraenkel, Liana ;

Bathon, Joan M. ;

England, Bryant R. ;

St Clair, E. William ;

Arayssi, Thurayya ;

Carandang, Kristine ;

Deane, Kevin D. ;

Genovese, Mark ;

Huston, Kent Kwas ;

Kerr, Gail ;

Kremer, Joel ;

Nakamura, Mary C. ;

Russell, Linda A. ;

Singh, Jasvinder A. ;

Smith, Benjamin J. ;

Sparks, Jeffrey A. ;

Venkatachalam, Shilpa ;

Weinblatt, Michael E. ;

Al-Gibbawi, Mounir ;

Baker, Joshua F. ;

Barbour, Kamil E. ;

Barton, Jennifer L. ;

Cappelli, Laura ;

Chamseddine, Fatimah ;

George, Michael ;

Johnson, Sindhu R. ;

Kahale, Lara ;

Karam, Basil S. ;

Khamis, Assem M. ;

Navarro-Millan, Iris ;

Mirza, Reza ;

Schwab, Pascale ;

Singh, Namrata ;

Turgunbaev, Marat ;

Turner, Amy S. ;

Yaacoub, Sally ;

Akl, Elie A. .

ARTHRITIS & RHEUMATOLOGY, 2021, 73 (07) :1108-1123

[5] Ozoralizumab, a Humanized Anti-TNFα NANOBODY(R) Compound, Exhibits Efficacy Not Only at the Onset of Arthritis in a Human TNF Transgenic Mouse but Also During Secondary Failure of Administration of an Anti-TNFα IgG [J].

Ishiwatari-Ogata, Chihiro ;

Kyuuma, Masanao ;

Ogata, Hitoshi ;

Yamakawa, Machi ;

Iwata, Katsuya ;

Ochi, Motoki ;

Hori, Miyuki ;

Miyata, Noriyuki ;

Fujii, Yasuyuki .

FRONTIERS IN IMMUNOLOGY, 2022, 13

[6] The Therapeutic Potential of Nanobodies [J].

Jovcevska, Ivana ;

Muyldermans, Serge .

BIODRUGS, 2020, 34 (01) :11-26

[7] Drug treatment algorithm and recommendations from the 2020 update of the Japan College of Rheumatology clinical practice guidelines for the management of rheumatoid arthritis-secondary publication [J].

Kawahito, Yutaka ;

Morinobu, Akio ;

Kaneko, Yuko ;

Kohno, Masataka ;

Hirata, Shintaro ;

Kishimoto, Mitsumasa ;

Seto, Yohei ;

Sugihara, Takahiko ;

Tanaka, Eiichi ;

Ito, Hiromu ;

Kojima, Toshihisa ;

Matsushita, Isao ;

Nishida, Keiichiro ;

Mori, Masaaki ;

Murashima, Atsuko ;

Yamanaka, Hisashi ;

Nakayama, Takeo ;

Kojima, Masayo ;

Harigai, Masayoshi .

MODERN RHEUMATOLOGY, 2023, 33 (01) :21-35

[8] Cytokines in rheumatoid arthritis - shaping the immunological landscape [J].

McInnes, Iain B. ;

Buckley, Christopher D. ;

Isaacs, John D. .

NATURE REVIEWS RHEUMATOLOGY, 2016, 12 (01) :63-68

[9]

Sanofi, 2021, NANOBODY TECHN PLATF

[10]

Sanofi Ablynx, 2018, SAN COMPL ITS ACQ AB

← 1 2 →